Matches in SemOpenAlex for { <https://semopenalex.org/work/W98923922> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W98923922 endingPage "223" @default.
- W98923922 startingPage "223" @default.
- W98923922 abstract "To review and update the contributions of a new class of drugs, named calcium channel alpha2delta protein ligands, on the treatment of epilepsy and neuropathic pain.A novel class of anticonvulsants are ligands for the auxiliary-associated protein alpha2delta subunit of voltage-gated calcium channels in the central nervous system. Gabapentin and pregabalin are members of this group. Pregabalin is a higher-potency and higher-effective analogue of gabapentin that act as a potent ligand for this site. The anticonvulsant action of pregabalin is probably due to its ability to reduce neurotransmitter release from activated epileptogenic neurons, without demonstrated effects on GABAergic receptors or mechanisms. In well-done clinical trials, pregabalin 150-600 mg/day has been shown to be highly effective and well tolerated as adjunctive therapy in patients with partial seizures. In several randomized, double-blind, clinical trials, oral pregabalin 150-600 mg/day was superior to placebo in relieving neuropathic pain associated with diabetic neuropathy and postherpetic neuralgia. Pregabalin demonstrates in humans an extensive and rapid absorption and a highly predictable and linear pharmacokinetics, a profile that makes it easy to use in clinical practice. The pharmacological activity of pregabalin is similar but not identical to that of gabapentin, and pregabalin shows possible advantages.Pregabalin and calcium channel alpha2delta protein ligands showed relevant advances on epilepsy and neuropathic pain treatment. In peripheral neuropathic pain conditions, if the criteria for efficacy are based on both pain relief and quality of life measures, pregabalin/gabapentin are suggested as choice treatment." @default.
- W98923922 created "2016-06-24" @default.
- W98923922 creator A5077123875 @default.
- W98923922 creator A5078802668 @default.
- W98923922 date "2006-01-01" @default.
- W98923922 modified "2023-09-30" @default.
- W98923922 title "Pregabalina. Aportaciones de los ligandos 2 de canales de calcio en el tratamiento de la epilepsia y el dolor neuropático" @default.
- W98923922 doi "https://doi.org/10.33588/rn.4204.2006038" @default.
- W98923922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16521062" @default.
- W98923922 hasPublicationYear "2006" @default.
- W98923922 type Work @default.
- W98923922 sameAs 98923922 @default.
- W98923922 citedByCount "7" @default.
- W98923922 countsByYear W989239222014 @default.
- W98923922 countsByYear W989239222018 @default.
- W98923922 crossrefType "journal-article" @default.
- W98923922 hasAuthorship W98923922A5077123875 @default.
- W98923922 hasAuthorship W98923922A5078802668 @default.
- W98923922 hasConcept C118552586 @default.
- W98923922 hasConcept C126322002 @default.
- W98923922 hasConcept C142724271 @default.
- W98923922 hasConcept C204787440 @default.
- W98923922 hasConcept C2775858608 @default.
- W98923922 hasConcept C2776468701 @default.
- W98923922 hasConcept C2776608144 @default.
- W98923922 hasConcept C2777107010 @default.
- W98923922 hasConcept C2778186239 @default.
- W98923922 hasConcept C2780820201 @default.
- W98923922 hasConcept C42219234 @default.
- W98923922 hasConcept C519063684 @default.
- W98923922 hasConcept C71924100 @default.
- W98923922 hasConcept C85520022 @default.
- W98923922 hasConcept C98274493 @default.
- W98923922 hasConceptScore W98923922C118552586 @default.
- W98923922 hasConceptScore W98923922C126322002 @default.
- W98923922 hasConceptScore W98923922C142724271 @default.
- W98923922 hasConceptScore W98923922C204787440 @default.
- W98923922 hasConceptScore W98923922C2775858608 @default.
- W98923922 hasConceptScore W98923922C2776468701 @default.
- W98923922 hasConceptScore W98923922C2776608144 @default.
- W98923922 hasConceptScore W98923922C2777107010 @default.
- W98923922 hasConceptScore W98923922C2778186239 @default.
- W98923922 hasConceptScore W98923922C2780820201 @default.
- W98923922 hasConceptScore W98923922C42219234 @default.
- W98923922 hasConceptScore W98923922C519063684 @default.
- W98923922 hasConceptScore W98923922C71924100 @default.
- W98923922 hasConceptScore W98923922C85520022 @default.
- W98923922 hasConceptScore W98923922C98274493 @default.
- W98923922 hasIssue "04" @default.
- W98923922 hasLocation W989239221 @default.
- W98923922 hasLocation W989239222 @default.
- W98923922 hasOpenAccess W98923922 @default.
- W98923922 hasPrimaryLocation W989239221 @default.
- W98923922 hasRelatedWork W1994334998 @default.
- W98923922 hasRelatedWork W2022694549 @default.
- W98923922 hasRelatedWork W2045765074 @default.
- W98923922 hasRelatedWork W2230184267 @default.
- W98923922 hasRelatedWork W2233988725 @default.
- W98923922 hasRelatedWork W2320992131 @default.
- W98923922 hasRelatedWork W2563265326 @default.
- W98923922 hasRelatedWork W2593565174 @default.
- W98923922 hasRelatedWork W2994702995 @default.
- W98923922 hasRelatedWork W3166948101 @default.
- W98923922 hasVolume "42" @default.
- W98923922 isParatext "false" @default.
- W98923922 isRetracted "false" @default.
- W98923922 magId "98923922" @default.
- W98923922 workType "article" @default.